Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis
Tiziano Barbui, Jürgen Thiele, Alessandra Carobbio, Francesco Passamonti, Elisa Rumi, Maria Luigia Randi, Irene Bertozzi, Alessandro M Vannucchi, Heinz Gisslinger, Bettina Gisslinger, Guido Finazzi, Marco Ruggeri, Francesco Rodeghiero, Alessandro Rambaldi, Naseema Gangat, Ayalew Tefferi, Tiziano Barbui, Jürgen Thiele, Alessandra Carobbio, Francesco Passamonti, Elisa Rumi, Maria Luigia Randi, Irene Bertozzi, Alessandro M Vannucchi, Heinz Gisslinger, Bettina Gisslinger, Guido Finazzi, Marco Ruggeri, Francesco Rodeghiero, Alessandro Rambaldi, Naseema Gangat, Ayalew Tefferi
Abstract
In the present study, we investigated disease characteristics and clinical outcome in young patients (< 40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) compared with early/prefibrotic primary myelofibrosis (PMF) with presenting thrombocythemia. We recruited 213 young patients (median age, 33.6 years), including 178 patients (84%) with WHO-defined ET and 35 patients (16%) showing early PMF. Median follow-up time was 7.5 years. A trend for more overall thrombotic complications, particularly arterial, was seen in early PMF compared with ET. Progression to overt myelofibrosis was 3% in ET and 9% in early PMF, but no transformation into acute leukemia was observed. Combining all adverse events (thrombosis, bleeding, and myelofibrosis), the rate was significantly different (1.29% vs 3.43% of patients/year, P = .01) in WHO-ET and early PMF, respectively. In multivariate analysis, early PMF and the JAK2V617F mutation emerged as independent factors predicting cumulative adverse events.
Source: PubMed